Stryker Corporation $SYK Shares Acquired by Thurston Springer Miller Herd & Titak Inc.

Thurston Springer Miller Herd & Titak Inc. boosted its stake in shares of Stryker Corporation (NYSE:SYK) by 255.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,742 shares of the medical technology company’s stock after acquiring an additional 2,688 shares during the quarter. Thurston Springer Miller Herd & Titak Inc.’s holdings in Stryker were worth $1,315,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of SYK. Clayton Financial Group LLC acquired a new stake in shares of Stryker during the 3rd quarter worth approximately $26,000. Elevation Point Wealth Partners LLC acquired a new position in shares of Stryker in the 2nd quarter valued at $28,000. Kilter Group LLC purchased a new stake in Stryker during the second quarter worth $29,000. Howard Hughes Medical Institute purchased a new stake in Stryker during the second quarter worth $29,000. Finally, United Financial Planning Group LLC acquired a new stake in Stryker during the third quarter valued at $27,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Stryker Trading Down 0.0%

Shares of SYK stock opened at $331.48 on Friday. Stryker Corporation has a fifty-two week low of $319.32 and a fifty-two week high of $404.87. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.21 and a current ratio of 1.89. The stock’s fifty day moving average is $357.10 and its two-hundred day moving average is $361.96. The firm has a market capitalization of $126.95 billion, a P/E ratio of 39.46, a PEG ratio of 1.94 and a beta of 0.92.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, topping the consensus estimate of $4.40 by $0.07. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The firm had revenue of $7.17 billion for the quarter, compared to the consensus estimate of $7.12 billion. During the same period last year, the firm posted $4.01 earnings per share. The company’s revenue for the quarter was up 11.4% on a year-over-year basis. Research analysts expect that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend is Tuesday, March 31st. Stryker’s dividend payout ratio (DPR) is currently 41.90%.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 250,000 shares of Stryker stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the transaction, the director owned 2,457,331 shares in the company, valued at approximately $891,814,566.52. This trade represents a 9.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 5.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. Wall Street Zen upgraded shares of Stryker from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Jefferies Financial Group restated a “buy” rating and issued a $465.00 price target on shares of Stryker in a research note on Wednesday, March 4th. Needham & Company LLC upped their price target on Stryker from $448.00 to $454.00 and gave the stock a “buy” rating in a report on Friday, January 30th. Raymond James Financial upgraded Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 price target on the stock in a research report on Tuesday, January 6th. Finally, Sanford C. Bernstein boosted their price objective on Stryker from $450.00 to $465.00 and gave the company an “outperform” rating in a research report on Friday, January 9th. Fourteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Stryker has a consensus rating of “Moderate Buy” and a consensus price target of $427.50.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.